343 related articles for article (PubMed ID: 15865827)
21. [Humanized respiratory syncytial virus monoclonal antibody].
Tsutsumi H
Nihon Rinsho; 2002 Mar; 60(3):487-91. PubMed ID: 11904963
[TBL] [Abstract][Full Text] [Related]
22. Respiratory syncytial virus disease: update on treatment and prevention.
Krilov LR
Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
[TBL] [Abstract][Full Text] [Related]
23. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
Pediatrics; 1998 Sep; 102(3):531-7. PubMed ID: 9724660
[TBL] [Abstract][Full Text] [Related]
24. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
[TBL] [Abstract][Full Text] [Related]
25. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations.
Rackham OJ; Thorburn K; Kerr SJ
Cardiol Young; 2005 Jun; 15(3):251-5. PubMed ID: 15865826
[TBL] [Abstract][Full Text] [Related]
26. Palivizumab in prevention of bronchiolitis: new preparation. Moderate efficacy in some infants.
Prescrire Int; 2000 Dec; 9(50):171-2, 174. PubMed ID: 11475494
[TBL] [Abstract][Full Text] [Related]
27. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
Venkatesh MP; Weisman LE
Expert Rev Vaccines; 2006 Apr; 5(2):261-8. PubMed ID: 16608425
[TBL] [Abstract][Full Text] [Related]
28. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
29. [Respiratory syncytial virus].
Stensballe LG; Kristensen K
Ugeskr Laeger; 2002 Nov; 164(48):5623-6. PubMed ID: 12523006
[TBL] [Abstract][Full Text] [Related]
30. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: the CIVIC Epidemiologic Study.
Medrano C; Garcia-Guereta L; Grueso J; Insa B; Ballesteros F; Casaldaliga J; Cuenca V; Escudero F; de la Calzada LG; Luis M; Luque M; Mendoza A; Prada F; del Mar Rodríguez M; Suarez P; Quero C; Guilera M;
Cardiol Young; 2007 Aug; 17(4):360-71. PubMed ID: 17662160
[TBL] [Abstract][Full Text] [Related]
31. The impact of infection with human metapneumovirus and other respiratory viruses in young infants and children at high risk for severe pulmonary disease.
Klein MI; Coviello S; Bauer G; Benitez A; Serra ME; Schiatti MP; Delgado MF; Melendi GA; Novalli L; Pena HG; Karron RA; Kleeberger SR; Polack FP
J Infect Dis; 2006 Jun; 193(11):1544-51. PubMed ID: 16652283
[TBL] [Abstract][Full Text] [Related]
32. Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations.
Feltes TF; Groothuis JR
Cardiol Young; 2005 Jun; 15(3):266-73. PubMed ID: 15865828
[TBL] [Abstract][Full Text] [Related]
33. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
Winchester L; García L; García I; Concepción CB
P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108
[TBL] [Abstract][Full Text] [Related]
34. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
35. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
36. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
37. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
[TBL] [Abstract][Full Text] [Related]
39. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
Kurz H; Herbich K; Janata O; Sterniste W; Bauer K
J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
[TBL] [Abstract][Full Text] [Related]
40. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.
Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
